Ascentage wins first China reimbursement slot for lisaftoclax; olverembatinib stays listed
Both of the company's marketed leukaemia drugs will sit on China's state reimbursement list from 1 January 2027, though price and reimbursement terms were not disclosed.
Ascentage Pharma said on 16 November 2026 that both of its approved blood-cancer drugs will be covered by China's state insurance reimbursement list from 1 January 2027. For lisaftoclax this is its first appearance on the list. Olverembatinib keeps the place it already held.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Ascentage Pharma Group International ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.